Sanginita Chemicals Limited

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, UPL.BO has a market cap of 500.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while UPL.BO trades at ₹592.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas UPL.BO's P/E ratio is 28.30. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to UPL.BO's ROE of +0.05%. Regarding short-term risk, SANGINITA.NS is less volatile compared to UPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check UPL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, FLUOROCHEM.NS has a market cap of 351.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while FLUOROCHEM.NS trades at ₹3,203.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas FLUOROCHEM.NS's P/E ratio is 53.70. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to FLUOROCHEM.NS's ROE of +0.09%. Regarding short-term risk, SANGINITA.NS is less volatile compared to FLUOROCHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check FLUOROCHEM.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, DEEPAKNI.BO has a market cap of 332.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while DEEPAKNI.BO trades at ₹2,436.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas DEEPAKNI.BO's P/E ratio is 57.46. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DEEPAKNI.BO's ROE of +0.06%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DEEPAKNI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DEEPAKNI.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, NAVINFLUOR.NS has a market cap of 301.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while NAVINFLUOR.NS trades at ₹5,891.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas NAVINFLUOR.NS's P/E ratio is 54.54. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to NAVINFLUOR.NS's ROE of +0.19%. Regarding short-term risk, SANGINITA.NS is less volatile compared to NAVINFLUOR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check NAVINFLUOR.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, NAVINFLUOR.BO has a market cap of 301.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while NAVINFLUOR.BO trades at ₹5,883.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas NAVINFLUOR.BO's P/E ratio is 54.51. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to NAVINFLUOR.BO's ROE of +0.19%. Regarding short-term risk, SANGINITA.NS is less volatile compared to NAVINFLUOR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check NAVINFLUOR.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, BAYERCROP.BO has a market cap of 213.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while BAYERCROP.BO trades at ₹4,758.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas BAYERCROP.BO's P/E ratio is 31.86. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to BAYERCROP.BO's ROE of +0.23%. Regarding short-term risk, SANGINITA.NS is less volatile compared to BAYERCROP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check BAYERCROP.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, DEEPAKNTR.NS has a market cap of 187.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while DEEPAKNTR.NS trades at ₹1,377.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas DEEPAKNTR.NS's P/E ratio is 35.22. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DEEPAKNTR.NS's ROE of +0.10%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DEEPAKNTR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DEEPAKNTR.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, DEEPAKNTR.BO has a market cap of 187.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while DEEPAKNTR.BO trades at ₹1,377.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas DEEPAKNTR.BO's P/E ratio is 35.20. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DEEPAKNTR.BO's ROE of +0.10%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DEEPAKNTR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DEEPAKNTR.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, TATACHEM.BO has a market cap of 166.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while TATACHEM.BO trades at ₹652.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas TATACHEM.BO's P/E ratio is 102.13. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to TATACHEM.BO's ROE of +0.01%. Regarding short-term risk, SANGINITA.NS is less volatile compared to TATACHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check TATACHEM.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, TATACHEM.NS has a market cap of 166.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while TATACHEM.NS trades at ₹651.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas TATACHEM.NS's P/E ratio is 102.50. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to TATACHEM.NS's ROE of +0.01%. Regarding short-term risk, SANGINITA.NS is less volatile compared to TATACHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check TATACHEM.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, SPLPETRO.NS has a market cap of 137.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while SPLPETRO.NS trades at ₹732.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas SPLPETRO.NS's P/E ratio is 51.39. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to SPLPETRO.NS's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is less volatile compared to SPLPETRO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check SPLPETRO.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, DEEPAKFERT.BO has a market cap of 125.6B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while DEEPAKFERT.BO trades at ₹994.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas DEEPAKFERT.BO's P/E ratio is 14.36. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DEEPAKFERT.BO's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DEEPAKFERT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DEEPAKFERT.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, DEEPAKFERT.NS has a market cap of 125.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while DEEPAKFERT.NS trades at ₹992.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas DEEPAKFERT.NS's P/E ratio is 14.31. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DEEPAKFERT.NS's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DEEPAKFERT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DEEPAKFERT.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, ACI.BO has a market cap of 72.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while ACI.BO trades at ₹584.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas ACI.BO's P/E ratio is 49.33. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ACI.BO's ROE of +0.08%. Regarding short-term risk, SANGINITA.NS is less volatile compared to ACI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check ACI.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, ACI.NS has a market cap of 72.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while ACI.NS trades at ₹583.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas ACI.NS's P/E ratio is 49.19. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ACI.NS's ROE of +0.08%. Regarding short-term risk, SANGINITA.NS is less volatile compared to ACI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check ACI.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, INDIAGLYCO.NS has a market cap of 60B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while INDIAGLYCO.NS trades at ₹894.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas INDIAGLYCO.NS's P/E ratio is 20.70. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INDIAGLYCO.NS's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is less volatile compared to INDIAGLYCO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check INDIAGLYCO.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, INDIAGLYCO.BO has a market cap of 59.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while INDIAGLYCO.BO trades at ₹892.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas INDIAGLYCO.BO's P/E ratio is 21.31. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INDIAGLYCO.BO's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is less volatile compared to INDIAGLYCO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check INDIAGLYCO.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, GNFC.BO has a market cap of 58.6B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while GNFC.BO trades at ₹398.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas GNFC.BO's P/E ratio is 9.21. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GNFC.BO's ROE of +0.07%. Regarding short-term risk, SANGINITA.NS is less volatile compared to GNFC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check GNFC.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, GNFC.NS has a market cap of 58.6B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while GNFC.NS trades at ₹398.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas GNFC.NS's P/E ratio is 9.40. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GNFC.NS's ROE of +0.07%. Regarding short-term risk, SANGINITA.NS is less volatile compared to GNFC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check GNFC.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, GUJALKALI.NS has a market cap of 44.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while GUJALKALI.NS trades at ₹603.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas GUJALKALI.NS's P/E ratio is -511.40. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GUJALKALI.NS's ROE of -0.00%. Regarding short-term risk, SANGINITA.NS is less volatile compared to GUJALKALI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check GUJALKALI.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, GUJALKALI.BO has a market cap of 44.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while GUJALKALI.BO trades at ₹602.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas GUJALKALI.BO's P/E ratio is -506.05. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GUJALKALI.BO's ROE of -0.00%. Regarding short-term risk, SANGINITA.NS is less volatile compared to GUJALKALI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check GUJALKALI.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, MFL.NS has a market cap of 44.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while MFL.NS trades at ₹1,062.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas MFL.NS's P/E ratio is 15.94. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to MFL.NS's ROE of +0.39%. Regarding short-term risk, SANGINITA.NS is less volatile compared to MFL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check MFL.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, GHCL.NS has a market cap of 41.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while GHCL.NS trades at ₹454.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas GHCL.NS's P/E ratio is 8.54. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GHCL.NS's ROE of +0.15%. Regarding short-term risk, SANGINITA.NS is less volatile compared to GHCL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check GHCL.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, GHCL.BO has a market cap of 41.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while GHCL.BO trades at ₹454.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas GHCL.BO's P/E ratio is 8.53. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GHCL.BO's ROE of +0.15%. Regarding short-term risk, SANGINITA.NS is less volatile compared to GHCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check GHCL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, CHEMPLASTS.BO has a market cap of 40.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while CHEMPLASTS.BO trades at ₹257.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas CHEMPLASTS.BO's P/E ratio is -14.25. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to CHEMPLASTS.BO's ROE of -0.15%. Regarding short-term risk, SANGINITA.NS is less volatile compared to CHEMPLASTS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check CHEMPLASTS.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, CHEMPLASTS.NS has a market cap of 40.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while CHEMPLASTS.NS trades at ₹256.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas CHEMPLASTS.NS's P/E ratio is -14.19. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to CHEMPLASTS.NS's ROE of -0.15%. Regarding short-term risk, SANGINITA.NS is less volatile compared to CHEMPLASTS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check CHEMPLASTS.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, EPIGRAL.NS has a market cap of 38.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while EPIGRAL.NS trades at ₹883.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas EPIGRAL.NS's P/E ratio is 11.28. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to EPIGRAL.NS's ROE of +0.18%. Regarding short-term risk, SANGINITA.NS is less volatile compared to EPIGRAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check EPIGRAL.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, EPIGRAL.BO has a market cap of 38.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while EPIGRAL.BO trades at ₹883.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas EPIGRAL.BO's P/E ratio is 11.27. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to EPIGRAL.BO's ROE of +0.18%. Regarding short-term risk, SANGINITA.NS is less volatile compared to EPIGRAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check EPIGRAL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, RAIN.BO has a market cap of 38.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while RAIN.BO trades at ₹113.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas RAIN.BO's P/E ratio is 89.84. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to RAIN.BO's ROE of +0.01%. Regarding short-term risk, SANGINITA.NS is less volatile compared to RAIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check RAIN.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, RAIN.NS has a market cap of 38B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while RAIN.NS trades at ₹113.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas RAIN.NS's P/E ratio is 89.75. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to RAIN.NS's ROE of +0.01%. Regarding short-term risk, SANGINITA.NS is less volatile compared to RAIN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check RAIN.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, MEGH.NS has a market cap of 35.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while MEGH.NS trades at ₹139.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas MEGH.NS's P/E ratio is 15.63. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to MEGH.NS's ROE of +0.16%. Regarding short-term risk, SANGINITA.NS is less volatile compared to MEGH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check MEGH.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, STYRENIX.BO has a market cap of 32.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while STYRENIX.BO trades at ₹1,839.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas STYRENIX.BO's P/E ratio is 19.53. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to STYRENIX.BO's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is less volatile compared to STYRENIX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check STYRENIX.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, STYRENIX.NS has a market cap of 32.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while STYRENIX.NS trades at ₹1,829.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas STYRENIX.NS's P/E ratio is 19.42. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to STYRENIX.NS's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is less volatile compared to STYRENIX.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check STYRENIX.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, FOSECOIND.NS has a market cap of 29.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while FOSECOIND.NS trades at ₹4,624.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas FOSECOIND.NS's P/E ratio is 41.93. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to FOSECOIND.NS's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is less volatile compared to FOSECOIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check FOSECOIND.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, FOSECOIND.BO has a market cap of 29.4B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while FOSECOIND.BO trades at ₹4,607.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas FOSECOIND.BO's P/E ratio is 37.15. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to FOSECOIND.BO's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is less volatile compared to FOSECOIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check FOSECOIND.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, RPEL.NS has a market cap of 28.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while RPEL.NS trades at ₹626.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas RPEL.NS's P/E ratio is 57.93. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to RPEL.NS's ROE of +0.24%. Regarding short-term risk, SANGINITA.NS is less volatile compared to RPEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check RPEL.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, RPEL.BO has a market cap of 28.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while RPEL.BO trades at ₹626.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas RPEL.BO's P/E ratio is 57.91. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to RPEL.BO's ROE of +0.26%. Regarding short-term risk, SANGINITA.NS is less volatile compared to RPEL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check RPEL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, ELLEN.NS has a market cap of 27.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while ELLEN.NS trades at ₹197.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas ELLEN.NS's P/E ratio is N/A. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ELLEN.NS's ROE of +0.09%. Regarding short-term risk, SANGINITA.NS is less volatile compared to ELLEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check ELLEN.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, DDEVPLASTIK.BO has a market cap of 27.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while DDEVPLASTIK.BO trades at ₹262.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas DDEVPLASTIK.BO's P/E ratio is 14.39. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DDEVPLASTIK.BO's ROE of +0.18%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DDEVPLASTIK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DDEVPLASTIK.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, BEPL.NS has a market cap of 21.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while BEPL.NS trades at ₹87.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas BEPL.NS's P/E ratio is 12.90. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to BEPL.NS's ROE of +0.17%. Regarding short-term risk, SANGINITA.NS is less volatile compared to BEPL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check BEPL.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, BEPL.BO has a market cap of 21.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while BEPL.BO trades at ₹87.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas BEPL.BO's P/E ratio is 13.01. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to BEPL.BO's ROE of +0.17%. Regarding short-term risk, SANGINITA.NS is less volatile compared to BEPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check BEPL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, GODAVARIB.NS has a market cap of 16B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while GODAVARIB.NS trades at ₹312.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas GODAVARIB.NS's P/E ratio is 45.57. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GODAVARIB.NS's ROE of +0.03%. Regarding short-term risk, SANGINITA.NS is less volatile compared to GODAVARIB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check GODAVARIB.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, INEOSSTYRO.NS has a market cap of 14.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while INEOSSTYRO.NS trades at ₹807.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas INEOSSTYRO.NS's P/E ratio is 11.53. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INEOSSTYRO.NS's ROE of +0.23%. Regarding short-term risk, SANGINITA.NS is less volatile compared to INEOSSTYRO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check INEOSSTYRO.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, SANSTAR.NS has a market cap of 14.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while SANSTAR.NS trades at ₹77.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas SANSTAR.NS's P/E ratio is 74.79. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to SANSTAR.NS's ROE of +0.03%. Regarding short-term risk, SANGINITA.NS is less volatile compared to SANSTAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check SANSTAR.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, DCW.NS has a market cap of 12B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while DCW.NS trades at ₹40.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas DCW.NS's P/E ratio is 28.91. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DCW.NS's ROE of +0.04%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DCW.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DCW.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, DCW.BO has a market cap of 12B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while DCW.BO trades at ₹40.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas DCW.BO's P/E ratio is 24.09. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DCW.BO's ROE of +0.04%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DCW.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DCW.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, PUNJABCHEM.BO has a market cap of 11.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while PUNJABCHEM.BO trades at ₹950.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas PUNJABCHEM.BO's P/E ratio is 19.41. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to PUNJABCHEM.BO's ROE of +0.16%. Regarding short-term risk, SANGINITA.NS is less volatile compared to PUNJABCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check PUNJABCHEM.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, PUNJABCHEM.NS has a market cap of 11.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while PUNJABCHEM.NS trades at ₹940.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas PUNJABCHEM.NS's P/E ratio is 19.23. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to PUNJABCHEM.NS's ROE of +0.16%. Regarding short-term risk, SANGINITA.NS is less volatile compared to PUNJABCHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check PUNJABCHEM.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, IGPL.BO has a market cap of 10.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while IGPL.BO trades at ₹349.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas IGPL.BO's P/E ratio is 33.10. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to IGPL.BO's ROE of -0.01%. Regarding short-term risk, SANGINITA.NS is less volatile compared to IGPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check IGPL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, ANDHRSUGAR.NS has a market cap of 9.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while ANDHRSUGAR.NS trades at ₹73.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas ANDHRSUGAR.NS's P/E ratio is 11.91. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ANDHRSUGAR.NS's ROE of +0.05%. Regarding short-term risk, SANGINITA.NS is less volatile compared to ANDHRSUGAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check ANDHRSUGAR.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, ANDHRSUGAR.BO has a market cap of 9.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while ANDHRSUGAR.BO trades at ₹73.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas ANDHRSUGAR.BO's P/E ratio is 11.91. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ANDHRSUGAR.BO's ROE of +0.05%. Regarding short-term risk, SANGINITA.NS is less volatile compared to ANDHRSUGAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check ANDHRSUGAR.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, GULPOLY.NS has a market cap of 9.4B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while GULPOLY.NS trades at ₹150.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas GULPOLY.NS's P/E ratio is 12.25. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GULPOLY.NS's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is less volatile compared to GULPOLY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check GULPOLY.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, GULPOLY.BO has a market cap of 9.4B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while GULPOLY.BO trades at ₹150.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas GULPOLY.BO's P/E ratio is 12.28. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GULPOLY.BO's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is less volatile compared to GULPOLY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check GULPOLY.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, ZUARI.BO has a market cap of 8.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while ZUARI.BO trades at ₹201.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas ZUARI.BO's P/E ratio is 0.88. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ZUARI.BO's ROE of +0.41%. Regarding short-term risk, SANGINITA.NS is less volatile compared to ZUARI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check ZUARI.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, ORIENTCQ.BO has a market cap of 8.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while ORIENTCQ.BO trades at ₹810.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas ORIENTCQ.BO's P/E ratio is 15.88. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ORIENTCQ.BO's ROE of +0.01%. Regarding short-term risk, SANGINITA.NS is less volatile compared to ORIENTCQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check ORIENTCQ.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, GEMAROMA.NS has a market cap of 8B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while GEMAROMA.NS trades at ₹152.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas GEMAROMA.NS's P/E ratio is 28.40. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GEMAROMA.NS's ROE of +0.08%. Regarding short-term risk, SANGINITA.NS is less volatile compared to GEMAROMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check GEMAROMA.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, INDOBORAX.BO has a market cap of 7.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while INDOBORAX.BO trades at ₹247.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas INDOBORAX.BO's P/E ratio is 17.26. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INDOBORAX.BO's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is less volatile compared to INDOBORAX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check INDOBORAX.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, INDOBORAX.NS has a market cap of 7.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while INDOBORAX.NS trades at ₹246.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas INDOBORAX.NS's P/E ratio is 17.17. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INDOBORAX.NS's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is less volatile compared to INDOBORAX.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check INDOBORAX.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, AMNPLST.NS has a market cap of 7.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while AMNPLST.NS trades at ₹140.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas AMNPLST.NS's P/E ratio is 22.78. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to AMNPLST.NS's ROE of +0.13%. Regarding short-term risk, SANGINITA.NS is less volatile compared to AMNPLST.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check AMNPLST.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, AMNPLST.BO has a market cap of 7.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while AMNPLST.BO trades at ₹140.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas AMNPLST.BO's P/E ratio is 22.65. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to AMNPLST.BO's ROE of +0.13%. Regarding short-term risk, SANGINITA.NS is less volatile compared to AMNPLST.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check AMNPLST.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, A1L.BO has a market cap of 7.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while A1L.BO trades at ₹15.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas A1L.BO's P/E ratio is 198.13. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to A1L.BO's ROE of +0.03%. Regarding short-term risk, SANGINITA.NS and A1L.BO have similar daily volatility (0.00).Check A1L.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, SRHHYPOLTD.BO has a market cap of 7.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while SRHHYPOLTD.BO trades at ₹424.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas SRHHYPOLTD.BO's P/E ratio is 7.79. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to SRHHYPOLTD.BO's ROE of +0.10%. Regarding short-term risk, SANGINITA.NS is less volatile compared to SRHHYPOLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check SRHHYPOLTD.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, SRHHYPOLTD.NS has a market cap of 7.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while SRHHYPOLTD.NS trades at ₹421.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas SRHHYPOLTD.NS's P/E ratio is 7.74. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to SRHHYPOLTD.NS's ROE of +0.10%. Regarding short-term risk, SANGINITA.NS is less volatile compared to SRHHYPOLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check SRHHYPOLTD.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, INDOAMIN.NS has a market cap of 7B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while INDOAMIN.NS trades at ₹96.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas INDOAMIN.NS's P/E ratio is 9.83. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INDOAMIN.NS's ROE of +0.22%. Regarding short-term risk, SANGINITA.NS is less volatile compared to INDOAMIN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check INDOAMIN.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, INDOAMIN.BO has a market cap of 7B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while INDOAMIN.BO trades at ₹96.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas INDOAMIN.BO's P/E ratio is 9.77. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INDOAMIN.BO's ROE of +0.22%. Regarding short-term risk, SANGINITA.NS is less volatile compared to INDOAMIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check INDOAMIN.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, UNIENTER.NS has a market cap of 6.6B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while UNIENTER.NS trades at ₹95.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas UNIENTER.NS's P/E ratio is 33.37. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to UNIENTER.NS's ROE of +0.01%. Regarding short-term risk, SANGINITA.NS is less volatile compared to UNIENTER.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check UNIENTER.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, VALIANTORG.NS has a market cap of 6.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while VALIANTORG.NS trades at ₹232.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas VALIANTORG.NS's P/E ratio is 27.11. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to VALIANTORG.NS's ROE of +0.03%. Regarding short-term risk, SANGINITA.NS is less volatile compared to VALIANTORG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check VALIANTORG.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, VALIANTORG.BO has a market cap of 6.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while VALIANTORG.BO trades at ₹232.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas VALIANTORG.BO's P/E ratio is 27.05. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to VALIANTORG.BO's ROE of +0.03%. Regarding short-term risk, SANGINITA.NS is less volatile compared to VALIANTORG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check VALIANTORG.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, NATPEROX.BO has a market cap of 6B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while NATPEROX.BO trades at ₹1,040.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas NATPEROX.BO's P/E ratio is 399.75. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to NATPEROX.BO's ROE of -0.02%. Regarding short-term risk, SANGINITA.NS is less volatile compared to NATPEROX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check NATPEROX.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, SUNSHIEL.BO has a market cap of 5.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while SUNSHIEL.BO trades at ₹752.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas SUNSHIEL.BO's P/E ratio is 23.31. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to SUNSHIEL.BO's ROE of +0.25%. Regarding short-term risk, SANGINITA.NS is less volatile compared to SUNSHIEL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check SUNSHIEL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, DMCC.BO has a market cap of 5.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while DMCC.BO trades at ₹210.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas DMCC.BO's P/E ratio is 20.10. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DMCC.BO's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DMCC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DMCC.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, DMCC.NS has a market cap of 5.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while DMCC.NS trades at ₹209.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas DMCC.NS's P/E ratio is 19.98. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DMCC.NS's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DMCC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DMCC.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, PRIMO.NS has a market cap of 5.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while PRIMO.NS trades at ₹21.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas PRIMO.NS's P/E ratio is 93.13. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to PRIMO.NS's ROE of +0.02%. Regarding short-term risk, SANGINITA.NS is less volatile compared to PRIMO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check PRIMO.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, ARIES.BO has a market cap of 4.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while ARIES.BO trades at ₹342.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas ARIES.BO's P/E ratio is 10.22. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ARIES.BO's ROE of +0.15%. Regarding short-term risk, SANGINITA.NS is less volatile compared to ARIES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check ARIES.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, OCCLLTD.NS has a market cap of 4.4B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while OCCLLTD.NS trades at ₹87.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas OCCLLTD.NS's P/E ratio is 11.79. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to OCCLLTD.NS's ROE of +0.09%. Regarding short-term risk, SANGINITA.NS is less volatile compared to OCCLLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check OCCLLTD.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, SHIVALIK.BO has a market cap of 3.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while SHIVALIK.BO trades at ₹237.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas SHIVALIK.BO's P/E ratio is 32.16. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to SHIVALIK.BO's ROE of +0.02%. Regarding short-term risk, SANGINITA.NS is less volatile compared to SHIVALIK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check SHIVALIK.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, NAPEROL.BO has a market cap of 3.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while NAPEROL.BO trades at ₹557.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas NAPEROL.BO's P/E ratio is 34.54. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to NAPEROL.BO's ROE of -0.02%. Regarding short-term risk, SANGINITA.NS is less volatile compared to NAPEROL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check NAPEROL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, LORDSCHLO.BO has a market cap of 3.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while LORDSCHLO.BO trades at ₹123.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas LORDSCHLO.BO's P/E ratio is 12.40. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to LORDSCHLO.BO's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is less volatile compared to LORDSCHLO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check LORDSCHLO.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, LORDSCHLO.NS has a market cap of 3.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while LORDSCHLO.NS trades at ₹123.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas LORDSCHLO.NS's P/E ratio is 12.31. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to LORDSCHLO.NS's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is less volatile compared to LORDSCHLO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check LORDSCHLO.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, DCMSRMIND.BO has a market cap of 3.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while DCMSRMIND.BO trades at ₹175.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas DCMSRMIND.BO's P/E ratio is 3.63. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DCMSRMIND.BO's ROE of +0.05%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DCMSRMIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DCMSRMIND.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, KANORICHEM.NS has a market cap of 2.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while KANORICHEM.NS trades at ₹64.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas KANORICHEM.NS's P/E ratio is -3.79. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to KANORICHEM.NS's ROE of -0.08%. Regarding short-term risk, SANGINITA.NS is less volatile compared to KANORICHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check KANORICHEM.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, KANORICHEM.BO has a market cap of 2.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while KANORICHEM.BO trades at ₹63.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas KANORICHEM.BO's P/E ratio is -3.75. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to KANORICHEM.BO's ROE of -0.08%. Regarding short-term risk, SANGINITA.NS is less volatile compared to KANORICHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check KANORICHEM.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, DIAMINESQ.BO has a market cap of 2.4B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while DIAMINESQ.BO trades at ₹245.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas DIAMINESQ.BO's P/E ratio is -26.38. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DIAMINESQ.BO's ROE of -0.06%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DIAMINESQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DIAMINESQ.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, DIAMINESQ.NS has a market cap of 2.4B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while DIAMINESQ.NS trades at ₹244.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas DIAMINESQ.NS's P/E ratio is -26.22. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DIAMINESQ.NS's ROE of -0.06%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DIAMINESQ.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DIAMINESQ.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, OCCL.NS has a market cap of 2.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while OCCL.NS trades at ₹233.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas OCCL.NS's P/E ratio is 77.52. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to OCCL.NS's ROE of +0.02%. Regarding short-term risk, SANGINITA.NS and OCCL.NS have similar daily volatility (0.00).Check OCCL.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, INDGELA.BO has a market cap of 2.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while INDGELA.BO trades at ₹316.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas INDGELA.BO's P/E ratio is 8.53. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INDGELA.BO's ROE of +0.15%. Regarding short-term risk, SANGINITA.NS is less volatile compared to INDGELA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check INDGELA.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, JAYSYNTH.BO has a market cap of 1.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while JAYSYNTH.BO trades at ₹11.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas JAYSYNTH.BO's P/E ratio is 12.24. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to JAYSYNTH.BO's ROE of N/A. Regarding short-term risk, SANGINITA.NS is less volatile compared to JAYSYNTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check JAYSYNTH.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, ISHANCH.NS has a market cap of 1.4B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while ISHANCH.NS trades at ₹53.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas ISHANCH.NS's P/E ratio is -12.54. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ISHANCH.NS's ROE of -0.08%. Regarding short-term risk, SANGINITA.NS is less volatile compared to ISHANCH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check ISHANCH.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, PAUSHAKLTD.BO has a market cap of 1.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while PAUSHAKLTD.BO trades at ₹402.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas PAUSHAKLTD.BO's P/E ratio is 27.20. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to PAUSHAKLTD.BO's ROE of +0.08%. Regarding short-term risk, SANGINITA.NS is less volatile compared to PAUSHAKLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check PAUSHAKLTD.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, RESGEN.BO has a market cap of 1.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while RESGEN.BO trades at ₹56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas RESGEN.BO's P/E ratio is 14.40. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to RESGEN.BO's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is less volatile compared to RESGEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check RESGEN.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, CHEMCRUX.BO has a market cap of 1B. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while CHEMCRUX.BO trades at ₹68.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas CHEMCRUX.BO's P/E ratio is 48.88. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to CHEMCRUX.BO's ROE of +0.03%. Regarding short-term risk, SANGINITA.NS is less volatile compared to CHEMCRUX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check CHEMCRUX.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, DEEPAKCHEM.BO has a market cap of 842M. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while DEEPAKCHEM.BO trades at ₹77.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas DEEPAKCHEM.BO's P/E ratio is 7.52. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DEEPAKCHEM.BO's ROE of +0.19%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DEEPAKCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DEEPAKCHEM.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, POLYCHEM.BO has a market cap of 830.3M. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while POLYCHEM.BO trades at ₹2,055.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas POLYCHEM.BO's P/E ratio is 4.45. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to POLYCHEM.BO's ROE of +0.40%. Regarding short-term risk, SANGINITA.NS is less volatile compared to POLYCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check POLYCHEM.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, PARAGON.NS has a market cap of 767M. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while PARAGON.NS trades at ₹39.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas PARAGON.NS's P/E ratio is 8.95. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to PARAGON.NS's ROE of N/A. Regarding short-term risk, SANGINITA.NS is less volatile compared to PARAGON.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check PARAGON.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, ASHOKALC.BO has a market cap of 551.4M. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while ASHOKALC.BO trades at ₹119.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas ASHOKALC.BO's P/E ratio is -10.04. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ASHOKALC.BO's ROE of +0.05%. Regarding short-term risk, SANGINITA.NS is less volatile compared to ASHOKALC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check ASHOKALC.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, GARODCH.BO has a market cap of 482.7M. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while GARODCH.BO trades at ₹138.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas GARODCH.BO's P/E ratio is 76.21. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GARODCH.BO's ROE of -1.14%. Regarding short-term risk, SANGINITA.NS and GARODCH.BO have similar daily volatility (0.00).Check GARODCH.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, SHIVAAGRO.BO has a market cap of 411.2M. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while SHIVAAGRO.BO trades at ₹41.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas SHIVAAGRO.BO's P/E ratio is 187.05. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to SHIVAAGRO.BO's ROE of +0.00%. Regarding short-term risk, SANGINITA.NS is less volatile compared to SHIVAAGRO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check SHIVAAGRO.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, TRELCHE-B.BO has a market cap of 392.2M. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while TRELCHE-B.BO trades at ₹20.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas TRELCHE-B.BO's P/E ratio is N/A. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to TRELCHE-B.BO's ROE of N/A. Regarding short-term risk, SANGINITA.NS is less volatile compared to TRELCHE-B.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check TRELCHE-B.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 505.3M. In comparison, ZR2.BO has a market cap of 387.3M. Regarding current trading prices, SANGINITA.NS is priced at ₹19.51, while ZR2.BO trades at ₹108.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -14.89, whereas ZR2.BO's P/E ratio is 401.96. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ZR2.BO's ROE of +0.00%. Regarding short-term risk, SANGINITA.NS is less volatile compared to ZR2.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check ZR2.BO's competition here